AKR1C3 and diabetic neuropathy: Although the potency for inhibition of AKR1B1 is higher (Kurono et al. 2001; Matsumoto et al. 2009), therapeutic plasma concentrations of ranirestat, which is currently under development for the treatment of diabetic neuropathy (Bril et al. 2006; Sekiguchi et al. 2019; Itou et al. 2020) are in the micromolar range (Itou et al. 2020) and might, therefore, be high enough to efficaciously inhibit AKR1C3.